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Glycogen storage diseases (GSDs) are the heterogeneous group of disorders caused
by mutations in at least 30 different genes. Different types of GSDs, especially liver
GSDs, take overlapping symptoms and can be clinically indistinguishable. This survey
evaluated the use of whole-exome sequencing (WES) for the genetic analysis of the
liver GSD-suspected patients in three unrelated families. An in-house filtering pipeline
was used to assess rare pathogenic variants in GSD-associated genes, autosomal
recessive/mendelian disorder genes (carrier status for genetic counseling subjects), and
the ACMG’s list of 59 actionable genes. For the interpretation of the causative variants
and the incidental/secondary findings, ACMG guidelines were applied. Additionally,
we have explored PharmGKB class IA/IB pharmacogenetic variants. The segregation
analysis was performed using Sanger sequencing for the novel causative variants.
Bioinformatics analysis of the exome data in three individuals revealed three novel
homozygous causative variants in the GSD-associated genes. The first variant,
c.298_307delATGATCAACC in PYGL gene has related to HERS disease (GSD VI). Both
variants of c.1043dupT and c.613-1G > C in SLC2A2 gene have been associated
with Fanconi-Bickel syndrome (GSDXI). Eight pathogenic/likely pathogenic medical
actionable findings in Mendelian disease genes and 10 pharmacogenetic variants
with underlying drug response phenotypes have been identified. No known/expected
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pathogenic variants were detected in the ACMG’s list of 59 actionable genes. The logical
filtering steps can help in finding other medical actionable secondary/incidental findings
as well as effectively identifying the causative variants in heterogeneous conditions such
as GSDs. Three novel variants related to GSD genes recognized in liver GSD-suspected
patients with early infantile and childhood-age onset.
Keywords: glycogen storage diseases, whole-exome sequencing, novel causative variants, secondary/incidental
findings, pharmacogenetic variants
INTRODUCTION
Glycogen storage diseases (GSDs) are a group of rare inborn
errors of metabolism disorders caused by errors of specific
enzymes involving in glycogen degradation and synthesis. Based
on the enzyme deficiency and the involved tissue/s, GSDs are
classified into two major groups: liver GSDs and muscle GSDs.
Other organs such as the heart, and sometimes the central
nervous system can be commonly affected. There are nearly thirty
types of GSD, in which, the most common types, i.e., II, IIIa, V,
VII, IXd, X, XII, XIII, and XIV involve muscles (skeletal muscle
or heart) and types I, III, 0, XI, IX, VI, and IV mainly affect the
liver (Wang et al., 2012).
In general, the frequency of GSD is estimated to be in
2,000–43,000 live births. The clinical presentation is wide-range
from exercise intolerance, muscle- and heart-disturbance, and
sometimes rhabdomyolysis. Hepatomegaly and hypoglycemia are
the shared features of liver GSD types. GSDs have variations in
the age of onset, the severity of symptoms, morbidity, mortality,
and prognosis, which is associated with the specific causal
variant. Clinical symptoms may vary from severe (neonatal and
infantile) to almost asymptomatic or only exercise intolerance or
underestimate due to mild symptoms (Kishnani et al., 2010, 2014;
Laforet et al., 2012; Wang et al., 2012).
Different types of GSDs especially liver GSDs are clinically
indistinguishable with overlapping symptoms, even with the
occurrence of the same enzyme/mutation. The clinical symptoms
of GSD associated with the liver, such as GSD I, GSD III,
GSD IXa, and GSD XI, are similar to each other, while
the management/treatment may be different. Direct mutation
detection is the best method to confirm the clinical diagnosis and
classifying different forms of GSDs. Whole-exome sequencing
(WES) is an invaluable and essential tool to determine the
causative variants with accuracy and efficacy in heterogeneous
disorders such as GSDs.
Glycogen storage disease type VI (GSD-VI) and Fanconi-
Bickel syndrome (FBS) are the two types of GSDs that are
investigated in this study. GSD VI is a clinically and genetically
heterogeneous group of disorders with hepatomegaly, early
fasting hypoglycemia, growth retardation, and hyperlipidemia
(Guillam et al., 1997; Santer et al., 2002). This rare autosomal
recessive disorder with a frequency of 1:100,000 presents a
relatively mild disorder in infancy and childhood (Burwinkel
et al., 1998; Chang et al., 1998; Aeppli et al., 2020). It is caused by
compound heterozygous or homozygous mutations of the PYGL
gene (deficiency of liver phosphorylase) (Luo et al., 2020). PYGL
gene mutations inhibit the normal function of the liver glycogen
phosphorylase enzyme. This enzyme cleaves alpha 1,4-glycosidic
bonds to release glucose 1-phosphate from glycogen (Burwinkel
et al., 1998; Chang et al., 1998). The PYGL gene has 20 exons and
is located on chromosome 14. About 40 different mutations in the
PYGL gene have been reported (in the Human Gene Mutation
Database1), containing point mutations, splice-site mutations,
and deletions (Roscher et al., 2014).
Fanconi-Bickel syndrome also known as GSD type XI (GSD
XI), a rare disorder of carbohydrate metabolism with an
autosomal recessive mode of inheritance, was described first by
Fanconi and Bickel (1949). It is caused by missense, nonsense,
frame-shift (fs), in-frame indels, splice site, and compound
heterozygous mutations in the GLUT2 (SLC2A2) gene. More
than 100 cases of FBS with 70 specific mutations in this gene
have been identified so far (Sharari et al., 2020). SLC2A2 gene
mapped on chromosome 3q26.1-26.3 and encoded facilitative
glucose transporter protein 2 (GLUT2). SLC2A2 gene contains 11
exons and codes 524 amino acids (aa) which the transmembrane
segments of 9–12 show a major part in the typical affinity for
glucose. GLUT2 protein is expressed in hepatocytes, enterocytes,
pancreatic β-cells, and renal tubular cells (Sakamoto et al.,
2000; Sharari et al., 2020). Mutations in the SLC2A2 gene are
characterized by the accumulation of glycogen, specifically in
the liver and kidneys, failure to thrive, fasting hypoglycemia,
short stature, tubular nephropathy (glucosuria, proteinuria,
phosphaturia, bicarbonate wasting, and aminoaciduria), rickets,
and growth retardation. Additionally, FBS also has been reported
with phenotypic heterogeneity and variation in clinical severity
from mild presentation to overt diabetes mellitus (Şeker-Yılmaz
et al., 2017; Sharari et al., 2020).
In the present study, we performed WES to uncover the
disease-causing variants in three Iranian suspected liver GSD
patients. We assessed exomes by an in-house filtering pipeline
for rare likely pathogenic and pathogenic variants in 30 GSD-
associated genes for identifying causative variants associated
with the patient’s phenotype. To discover incidental/secondary
findings, we searched rare coding variants in other genes
associated with Mendelian diseases (carrier status for genetic
counseling subjects) in the Online Mendelian Inheritance in
Man (OMIM) database or on in the ACMG’s list of 59
actionable genes (associated with the preventable or curable
disease in childhood/adulthood) (Green et al., 2013; Kalia et al.,
2017). In addition, secondary pharmacogenetic variants in the
Pharmacogenomics Knowledgebase (PharmGKB class IA/IB)
and ClinVar were explored.
1http://www.hgmd.cf.ac.uk/ac/index.php
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MATERIALS AND METHODS
Subjects and Ethics Statement
Three patients (from three unrelated consanguineous families)
with the clinical diagnosis of hepatic/liver GSD were recruited
from the Taleqani Hospital and the Genomic Research Center in
Tehran, Iran, for the present study. Inclusion criteria were based
on clinical presentations of hepatomegaly, and biochemical
laboratory tests such as hypoglycemia, hypertriglyceridemia,
hyperlactatemia, hyperuricemia, and elevated aspartate
aminotransferase (AST) or alanine transaminase (ALT).
Assessment of serum phosphorus, serum calcium, and urine
analysis was also performed. WES was performed on three
affected GSD patients and identified variants were confirmed by
Sanger sequencing in their parents. Genetic counseling was done
with an expert genetic counselor and written informed consent
was achieved from all subjects and/or their parents. The study
was approved by the Ethical Committee of the Tehran University
of Medical Sciences.
Whole-Exome Sequencing
Peripheral blood samples of the three patients and their parents
were used to extract genomic DNA using the Salting out
procedure (Mwer et al., 1988). The patients (IV-2, IV-1, and
V-3) were subjected to WES using Agilent SureSelect V5
Target Enrichment Kit. The enriched library was sequenced
on an Illumina HighSeq4000 platform. Paired-end 101-bp
sequence reads were mapped to the UCSC human reference
genome (GRCh37/hg19 assembly) by Burrows-Wheeler Aligner
(BWA) (Li and Durbin, 2010). Duplicate and low-quality reads
(QBase < 20) were removed. Samtools (Li et al., 2009) was used
for sorting and indexing bam files. To call single nucleotide
variants (SNVs) and short insertions or deletions (Indels),
Genome Analysis Tool Kit (GATK) software package2 were
used. The VCF data were submitted to the Wannovar tool3 for
variant annotation.
Data Analysis (Variant Filtering)
An in-house filtering pipeline was conducted to detect the
causative variants. The stepwise approach for data analysis is
shown in Figure 1. The VCF annotated files were filtered to
catch rare pathogenic (P) and likely pathogenic (LP) variants
in OMIM genes; including the GSD-associated genes, the
list of 59 ACMG genes (Green et al., 2013; Kalia et al.,
2017), and other genes associated with Mendelian diseases
(the heterozygote variants/carrier status for genetic counseling).
Secondary pharmacogenetic variants were also investigated.
Common variants were excluded with minor allele
frequency > 0.05 in comparison within dbSNP4, 1000






database7, and gnomAD database8. Then intronic, synonymous,
upstream/downstream variants were removed but the 20–30 bp
flanking each exon was included in annotated files.
The remaining SNVs and Indels variants were prioritized as
follows: (a) known/unknown loss-of-function mutations (non-
sense, splice site, frameshift, in-frameshift variants, start-loss)
and missense mutations were selected and checked in ClinVar9
and HGMD10; (b) Bioinformatics prediction assessments to
evaluate the potential impact and pathogenicity of the candidate
causative variants on the function or structure of the protein
and conservation were directed by SIFT (Sim et al., 2012;
Vaser et al., 2016), PolyPhen2 (Adzhubei et al., 2013), Mutation
Taster (Schwarz et al., 2014), Combined Annotation Dependent
Depletion (CADD) (Kircher et al., 2014), DANN score (Quang
et al., 2015), and GERP score (Davydov et al., 2010); (c) the
Varsome and Interval tools which are based on ACMG-AMP
2015 Standards and Guidelines (Richards et al., 2015) were used
to interpret variants (Li and Wang, 2017; Kopanos et al., 2019).
To evaluate pharmacogenetic variants and drug efficacy, we
used the Clinical Pharmacogenetics Implementation Consortium
(CPIC), the PharmGKB database (1A/1B categories), and drug
responses based on ClinVar database. PGKB 1A/1B levels are the
substantive evidence for clinical relevance. Level 1A represents
annotation for a variant-drug combination in a CPIC and
Level 1B shows annotation for a variant-drug combination
with a replicated association in more than one cohort with
significant p-values.
Sanger Sequencing for Validation of the
Identified Mutations
Following data filtering, the identified causative variants were
confirmed by conventional Sanger sequencing in DNA samples of
the patients and their parents. For this purpose, specific primers
were designed with the Primer3 website11 and the amplicons were
directed to sequencing with ABI 3500 Genetic Analyzer (Applied
Biosystems, Foster City, CA, United States). The reference
sequences were used from the Ensemble12, and the data analysis
of sequencing results was done with Chromas v2.33 software.
RESULTS
Clinical Features of Patients
The proband (IV-2), a 5-year old boy (Figure 2) was a
consequence of a consanguineous marriage. He tended to
grow slower than his elder brother and midparental height.
However, at 5 years old, compared to the growth charts,
his weight (17.4 kg) and height (107 cm) were within the
normal ranges for his sex and age. There was also a history







Frontiers in Genetics | www.frontiersin.org 3 January 2021 | Volume 11 | Article 601566
fgene-11-601566 December 28, 2020 Time: 17:9 # 4
Eghbali et al. Discovering Novel Variants Using WES
FIGURE 1 | The workflow filtering of the causative variants and the secondary actionable findings in the patients for the WES results. The assessment of WES data
consists of filtering for rare known pathogenic (P) and likely pathogenic (LP) variants in genes in the OMIM database including the GSD-associated genes, the
ACMG’s list of 59 genes, and other genes associated with mendelian diseases (autosomal/X-linked recessive-related genes). For prioritizing expected pathogenic
variants, protein-truncating variants (PTMs) and missense variants were selected and bioinformatics prediction tools were used to evaluate the potential impact and
pathogenicity of the candidate variants (CADD score > 15 and mutation taster = disease causing). The identified variants were categorized and interpreted
according to the ACMG-AMP 2015 Standards and Guidelines. Besides, secondary pharmacogenetic variants in the Pharmacogenomics Knowledgebase
(PharmGKB class IA/IB) and ClinVar database were explored.
such as sitting, standing, or walking compared to his brother.
Other than a history of neonatal jaundice, he has no problems
until he was 3 years old when he experienced a fit after
overnight fasting on an early holiday morning. At that time
he was admitted to the hospital with a primary diagnosis of
“ketotic hypoglycemia of childhood” as there were low blood
sugar, mild metabolic acidosis, slightly elevated blood lactate,
and positive urine ketosis. On the other hand, physical and
ultrasound exams revealed a remarkable hepatomegaly. Other
positive findings were retarded bone age and elevated liver
enzymes. He was referred to the pediatric gastroenterology
section with a possible diagnosis of “GSD.” Where the parents
refused to take a liver biopsy and the kid was discharged
taking cornstarch four times a day, which was used for only
3 months. There were no further episodes of seizure or
laboratory findings of hypoglycemia, metabolic acidosis, elevated
blood lactate, uric acid, and hyperlipidemia in his outpatient
follow-up visits.
The proband (IV-1), an 8-month old boy (Figure 2)
was a result of a consanguineous marriage. There was no
family history of inherited metabolic disease. At birth, he
was 2.8 kg weight and 50 cm in length but suffered from
the poor weight (from 6 kg to 3.7 kg) in 8 months. He was
involved with neonatal hyperglycemia, which was improved
spontaneously in a few days. Then during the first few
months of life, he experienced failure to thrive, protruding
abdomen, and polyuria, and clinical manifestations of rickets
including widening of the wrist and bowing of the lower
limbs. During infancy and early childhood, he was admitted
to hospital several times due to severe growth retardation,
episodes of lethargy, poor feeding, and diarrhea. Radiologic
studies were in favor of rickets. Ultrasonography showed
hepatosplenomegaly and enlargement of kidneys. Laboratory
findings revealed normal anion gap, hyperchloremic metabolic
acidosis, fasting hypoglycemia, and post-feeding hyperglycemia,
hypokalemia, hypomagnesemia hypophosphatemia, elevated
Frontiers in Genetics | www.frontiersin.org 4 January 2021 | Volume 11 | Article 601566
fgene-11-601566 December 28, 2020 Time: 17:9 # 5
Eghbali et al. Discovering Novel Variants Using WES
FIGURE 2 | The family trees, BAM interfaces, and segregation analysis results. (A) The pedigrees of patients 1, 2, and 3 were shown in which their parents are
consanguine. (B) The WES reads were visualized by using the Integrative Genomics Viewer (IGV). (C) Sanger sequencing confirmation for the causative variants in
homozygous patients and unaffected heterozygous parents.
hepatic transaminases (ATS/ALT), proteinuria, glucosuria,
hyperphosphaturia, and non-specific aminoaciduria. Analysis
of liver biopsy samples revealed liver steatosis and glycogen
accumulation in the hepatocytes.
The 11-year-old girl [proband (V-3), Figure 2] was the result
of a kinship marriage with no family history of metabolic
disorders. Her weight at birth was 3.2 kg. According to her past
medical history, she was well in a few early months, but during
the second half of the first year of life severe growth retardation,
failure to thrive, hepatomegaly, and episodes of fever and lethargy
gradually appeared. There was a history of the retarded cutting of
the teeth, but no history of seizures, motor or cognitive decline,
and the speech and social skills were within the normal ranges for
age. She developed bone pain and walking difficulties following
a gradual progressive deformity of the legs as the clinical
manifestation of rickets and its complications since 10 months
old. At the age of 2, she weighed only 2.8 kg and was involved
with a severe failure to thrive and complicated rickets. Her main
clinical problems in 11 years bold were dwarfism with skeletal
deformities, protuberant abdomen due to hepatomegaly, moon-
shaped face, fat deposition about the shoulders and abdomen,
delayed puberty, osteoporosis with bone pain, and increased
risk of pathologic fractures. Laboratory assessment showed
hypoglycemia, ketonuria, glucosuria, proteinuria, increased
transaminases (ATS/ALT), reduced serum phosphorus, and
markedly elevated serum alkaline phosphatase levels. Normal
serum calcium and decreased vitamin D levels were also
recorded. Clinical and laboratory findings for the patients are
reported in Table 1.
Whole-Exome Sequencing Results
A summary of data analysis from the WES of the patients
is shown in Table 2. WES on proband (IV-2) was generated
7.4 GB sequences. The average depth of target regions reached
124X before mapping to the human reference genome sequence
(hg19) and after mapping, the average depth of target regions
reached 83X. Coverage data showed that 98.6% of the target
regions were sequenced at a more than depth of 10X reads.
WES of the second patient (proband IV-1) was produced
5.6 GB sequences and over 55 million read pairs (101 × 2)
were mapped. The mean depth of target regions reached 93X
before mapping to the reference genome and after mapping,
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TABLE 1 | Clinical and laboratory findings for the patients.






GSD type GSDVI GSDXI GSDXI
Mutation PYGL SLC2A2 SLC2A2
cDNA c.298_307del c.613-1G > C c.1043dupT
Protein p.M100Sfs*18 p.N349Kfs*44
Gender M M F
Age(years) 5 9 11
Age at onset 3 years 4 months 5 months
Age at diagnosis 4 years 8 months 1 year











Liver biopsy NA Compatible aspect with
GSD
NA
Hepatomegaly + + +
Hypoglycemia (<60 mg/dl) – + +
Increased AST/ALT (Up to 37 U/L)/(up to 41 U/L) +/+ +/+ +/+
Hyperlipidemia (>160 mg/dl) – – –
Hypercholesterolemia (>200 mg/dl) – – –
Hyperlactatemia (>2.5 mg/dl) – – –
Hyperuricemia (>5 mg/dl) – – –
Proteinuria – + +
Glucosuria – + +
Ketonuria – – +
Ammonemia – + NA
Hypophosphatemia (< 4 mg/dl) – + +
Increased alkaline phosphatase (>1200 U/L) – – +
Serum calcium (8–13 mg/dl) NA Decreased Normal
Vit D deficient (<20 ng/ml) Normal Normal Decreased
Other features – -Rickets -Anemia - Rickets
TABLE 2 | The summary report of data analysis from the WES.
Analytical characteristic Patient 1 (Proband IV-2) Patient 2 (Proband IV-1) Patient 3 (Proband V-3)
Total number of reads 74,227,000 55,298,288 72,367,238
Average read length (bp) 101 101 101
Target Region (Mbp) 60 60 60
% Bases QV>30 98.26 98.59 98.15
% Initial Mappable Reads 99 99 99
% Minimum coverage of target regions (for depth 1X, 5X and 10X) 99.8, 99.4 and 98.6 99.7, 99.2 and 97.4 97.8, 97.3 and 96.3
% of duplicate reads (pre-alignment) 24 20.5 29.24
% of duplicate reads (post-alignment) 6 5 8.7
% On Target Reads (post-alignment) 72 70 77
% Coverage >25X 91.34 81.77 88.41
% Coverage >50X 62.97 45.94 60.94
# of SNV 126,424 117,459 117,960
# of Stop Gained 90 104 91
# of Indels 12,603 10,527 11,116
the mean depth of target regions reached 65X. Coverage data
presented that 97.5% of the target regions were sequenced
at a minimum depth of 10X reads. The quality control of
7.3 GB of the third patient (proand V-3) revealed 97.8% of
the read bases had Q30. The throughput coverage of target
regions extended 121X before mapping to the reference genome
and after mapping, the mean depth of target regions was
77X. Furthermore, the analysis of sequencing data showed
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that 96.3% of the target regions were covered at a minimum
depth of 10X reads.
Genetic Findings
The filtering steps of the variants were performed based
on allele frequency < 0.05, mode of inheritance (keyword
search: autosomal recessive variants in GSD-associated genes),
pathogenic impacts of variants; such as CADD-PHRED
score > 10, mutation taster (disease-causing), pathogenic scores
in DANN Score (the value range is 0–1), and conservation
prediction tools such as GERP-score (ranging from −12.3
to 6.17). Finally, our filtering strategy revealed three novel
homozygous causative variants (two frameshift variants and
one splice site variant) in three GSD suspected patients. The
first frameshift variant, c.298_307delATGATCAACC (the
10 bp deletion), in exon 2 of PYGL gene was identified in
patient 1 (proband IV-2). The second frameshift variant,
c.1043dupT, in exon 7 of SLC2A2 gene was found in patient
3 (proband V-3). One novel splicing variant c.613-1G > C,
at end of the fifth intron of SLC2A2 gene was identified
in patient 2 (proband IV-1) as a homozygous variant.
Multiple lines of in silico analysis were used to evaluate the
pathogenicity of the variants which are shown in Table 3.
Sanger sequencing was used to confirm the WES results. The
identified causative variants in patients were homozygote
state, and unaffected parents were found to be heterozygote
state for the recognized variants (Figure 2). Other detected
variants (including eight mutations) in three patients were
secondary findings in Mendelian disease genes from the OMIM
database (data are available upon request). No pathogenic/likely
pathogenic variants have been found in the ACMG’s list of
59 actionable genes. The assessment of WES analysis revealed
10 pharmacogenetic variants that were at PharmGKB 1A/1B
levels (Table 4).
DISCUSSION
Glycogen storage diseases are a group of rare inherited metabolic
disorders that have clinical, locus, and allele heterogeneity. WES
has been recognized to be an effective method to identify
the genetic deficiencies in hereditary/mendelian disorders such
as metabolic disorders (Rabbani et al., 2014; Shakiba and
Keramatipour, 2018). In the present study, we conducted WES
and tried to interpret the results of the variant analysis in
three patients with liver GSD suspected diagnosis. Exome
analysis detected three causative variants in GSD-associated
genes including c.298_307delATGATCAACC (at PYGL gene;
associated with GADVI), c.613-1G > C, and c.1043dupT (at
SLC2A2 gene; associated with GSDXI). Computational analysis
and variant frequency in population databases are shown
in Table 3.
The detected variants in this study, frameshift, and splice
site variants are null alleles (loss-of-function mutations) which
lead to premature termination codons (PTCs). PTCs frequently
trigger non-sense-mediated decay (NMD) pathway as one of the
central mechanisms of RNA surveillance to degrade the mRNA,
so that no protein is prepared or a truncated protein is produced
(Kurosaki and Maquat, 2016).
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rs4149056 SLCO1B1 chr12:21331549 NM_006446.5 c.521T > C
p.V174A












rs1135840 CYP2D6 chr22:42522613 NM_000106.6 c.1457C > G
p.T486S


















rs35742686 CYP2D6 chr22:42524244 NM_000106.6 c.775delA
p. R259Gfs*2














rs16947 CYP2D6 chr22:42523943 NM_000106.6 c.886T > C
p. C296R






































































rs3745274 CYP2B6 chr19:41512841 NM_000767.5 c.516G >
p.Q172H




HIV infections Patient 3 (het)
Patient 2 (het)
rs7294 VKORC1 chr16:31102321 NM_000106.6 c.408C > G
p.V136 =








- Patient 3 (homo)
rs2228001 XPC chr3:14187449 NM_004628.5 c.2815C > A
p.Q939K





rs2279343 CYP2B6 chr19:41515263 NM_000767.5 c.785A > G
p.K262R
Missense 0.129 1A Efavirenz HIV infections Patient 2 (het)
rs1065852 CYP2D6 chr22:42526694 NM_000106.6 c.100C >
T p.P34S
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Regarding the two frameshift variants, p. M100Sfs∗18 in the
PYGL gene and p. N349Kfs∗44 in the SLC2A2 gene caused
by deletions of 10 nucleotides c.298_307delATGATCAACC and
insertion of one nucleotide c.1043dupT, respectively. When
several deleted or inserted nucleotides of a coding sequence
are not a multiple of three, a shift in the reading frame is
produced and so the original amino acid sequence is lost
(Guttmacher and Collins, 2002).
In the PYGL gene, 10 base pairs deletion impose a change
of methionine to serine at the 100th codon and leads to a
new reading frame that causes premature stop codon after
18 base pairs. This change may produce a truncated protein
with 116 aa residue.
Also, in the SLC2A2 gene, the insertion of one base pair
changes asparagine to lysine at codon 349 of exon 7. This
substitution leads to an early premature stop codon after 44
base pairs which produce a truncated protein with 391aa residue
shorter than the normal protein with 542 aa. In silico prediction
analysis Varsome (Kopanos et al., 2019) along with the manual
examination of the ACMG-AMP 2015 guidelines (Richards et al.,
2015) predicted that both frameshift variants are pathogenic:
(1) Null variant (frameshift) in a gene where LOF is a known
mechanism of disease (PVS1). (2) The absence of detected
variants in any of the population databases (PM2). (3) Multiple
prediction tools support a damaging effect on the gene or the
protein (PP3). (4) The patient’s phenotype is highly specific for
GSD with a single genetic etiology (PP4). These two variants
in the PYGL and SLC2A2 genes were validated by Sanger
sequencing in patients (as a homozygous variant) and their
parents (as a heterozygous variant).
Splice-site variants (canonical ± 1 or 2 splice sites) in major
regulatory elements are located at or close to splice junctions
often have significant effects on RNA splicing, especially if
they alter highly conserved nucleotides, such as in GT or and
AG dinucleotides at the 5′ and 3′ ends around any intron,
respectively. These splice site variants cause loss of coding exon
(by exon skipping or exon truncation) or a gain of coding
exon sequences (by exon extension or intron retention) which
may result in a translational frameshift at the RNA level. For
the c.613-1G > C variant, possible consequences of a G to C
substitution at the conserved 3′ splice-site consensus of intron
5 is to activate the splice acceptor site. The next splice acceptor
site (at the 3′ end of intron 6) could be used instead, therefore,
exon 6 will be skipped. As far as, the number of present
nucleotides in exon 6 is not a multiple of three, so the change
causes a frameshift in order of coding sequence. This frameshift
induces PTC as illustrated in Figure 3. As mentioned in Section
“Discussion,” in silico analyses of the effect of the c.613-1G > C
variant on the splicing pattern and the strength (% values) of
the acceptor splice site of exon 6 was predicted by the HSF
program version 313. Position weight (HSF) matrices predicted
that the substitution of c.613-1G > C results in broken of wild
type acceptor splice site with variation score (%) of wild type
broken site −32 for HSF and −66 for MaxEnt (according to
HSF and MaxEnt predictions, variation score under −10 and
−30%, respectively, the mutation breaks the splice site and most
probably affecting splicing; Desmet et al., 2009). Also, other
prediction tools based on ACMG guidelines such as Varsome and
Intervar tools indicated this variant is pathogenic based on this
evidence: PVS1, PM2, and PP3.
In conclusion, our results indicate that the novel splice variant,
c.613-1G > C, and the frameshift variant, p. N349Kfs∗44, in
the SLCA2 gene might be the genetic cause of FBS, and the
other frameshift variant, p. M100Sfs∗18, in PYGL gene might
be the genetic causes of GSD-VI. The recognized variants meet
the criteria of interpreting the variants as being pathogenic, but
we essentially advise applying functional analysis to study the
distinctive pathological roles of the variants.
13http://www.umd.be/HSF3/
FIGURE 3 | c.613-1G > C splice-site variant, can cause exon 6 skipping. Exon sequences are indicated with gray boxes and with capital letters to show
nucleotides. Intron sequences are represented as blue horizontal lines with lower case letters to show key conserved nucleotides in splicing. The green dashed lines
indicate the positions of splicing at the RNA level to bring together transcribed exon sequences. (A) A normal condition with three exons detached by introns with
conserved terminal dinucleotides (5′ GT and 3′ AG, around an intron). (B) A substitution G to C occurred at the conserved 3′ terminal nucleotide of intron 5, which
inactivate the splice acceptor site. As an alternative subsequent splice acceptor site of intron 6 could be used, which leads to skipping of exon 6 and following
inducing a frameshift [lead to a premature stop codon (TGA or UGA at RNA level) as indicated].
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We also assessed patients’ data for incidental or secondary
findings (in 59 genes listed in ACMG and OMIM genes) that are
unrelated to the primary phenotype of each patient. Our findings
and objectives can be categorized into two groups. First: The
goal of reporting known pathogenic (KP) or expected pathogenic
(EP) variants in the 59 gene list according to ACMG is to
identify and determine the risks associated with highly penetrant
genetic disorders over preventable or treatable interventions
(Green et al., 2013; Kalia et al., 2017). Second: we also evaluate
heterozygote pathogenic (P) and likely pathogenic (LP) variants
in genes associated with mendelian and recessive disorders. This
information on being heterozygote or carrier is important for
genetic counseling and family follow-up genetic screening. In
the present study, we did not identify any variant affecting the
protein function of the list of 59 ACMG genes, but in our patients,
we identified eight pathogenic/likely pathogenic heterozygous
variants (data are available upon request). These variants in
AR status may not be related to the patient’s phenotype, and
so determining the possible carrier status of their parents for
these variants is necessary before the next pregnancy. Therefore,
appropriate genetic counseling and suitable schedules must be
taken according to the genotype status of parents, for both their
parents and even genetic screening of their relatives.
Analysis of pharmacogenetic variants unveils 10 variants
reached a level 1A/1B classification in the PharmGKB database
(extracted from pharmgkb.org) is shown in Table 4. To
achieve more insight into the rare/common pharmacogenetic
variations, we used accessible and easily available databases
such as CPIC, PharmGKB, ClinVar, Pharmacogene Variation
(PharmVar) Consortium. For example, the rs4149056 variant,
with a MAF 0.13 in the GnomAD database, has a decreased
function missense variant in the SLCO1B1 gene. This variant
with heterozygous and homozygous states is accompanied
by an intermediate and high myopathy risk, respectively,
after getting simvastatin drug. If simvastatin is prescribed
to a patient with intermediate SLCO1B1 function as a
heterozygous variant, there is an increased risk for developing
simvastatin-associated myopathy; such cases might require a
lower starting dose of simvastatin or another statin agent
(Ramsey et al., 2014). Two variants (rs9934438, rs7294) in
VKORC1 gene have potential clinical utility. The genetic
variances in VKORC1 gene are dependent on the difference
in the final warfarin dose. Patients with the rs9934438 allele
need a lower warfarin dose compared with the wild-type carriers
(Wadelius et al., 2005). Patients with the rs7294 allele are
prescribed a higher warfarin dose (Wadelius et al., 2005; Herman
et al., 2006). Warfarin is a curative anticoagulant recommended
for persons at the possibility of thrombosis and embolism
(Owen et al., 2010).
However, in the local filtering of exome data, we detected
both rare and common pharmacogenetic variants in a set of
known genes in one research, our study has some limitations. We
neglected some variants such as copy number variations (CNVs)
and the majority of the intronic variants (as a result of lack of
coverage for these regions in WES). Other technical issues may
lead to undetected structural variants and the variants in highly
homologous regions of the human genome (Hočevar et al., 2019).
This may result in loosing some pharmacogenetic variants in
cytochrome genes such as CYP2D6.
In summary, WES of the patients suspected to GSD
diagnosis (with major symptoms such as hypoglycemia,
hepatomegaly, and growth retardation) indicated three novel
mutations associated with GSD-related genes. Two patients
with early infantile age-onset had the causative variants in
the SLC2A2 gene associated with GSD XI, while the patient
with the early childhood age-onset had the pathogenic variant
in the PYGL gene related to GSDVI. We hope that this
identification may produce new insights into the mechanisms
of pathogenesis of glycogen storage disorders. We also suggest
doing functional analysis to evaluate the possible pathogenesis
of the variants preceding to use in genetic counseling. Mutation
detection in affected individuals helps to define the exact
type of GSD and make the possibility of prenatal diagnosis
(PND) and preimplantation genetic diagnosis (PGD) in
families requiring this service. Here, we showed that WES
technologies have the potentiality of identifying not only
causative variants relevant to patients’ clinical manifestation
but also revealed secondary/incidental findings in genes
associated with AR disorders which have an impact on future
generations and reproduction decisions. Moreover, secondary
pharmacogenetics findings are important in personalized
treatment or guiding therapy.
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